The plasminogen activation system in tissue remodeling and cancer invasion

The Cancer Degradome: Proteases and Cancer Biology

Volumn , Issue , 2008, Pages 203-221

  Almholt, Kasper ^a   Juncker Jensen, Anna ^b   Green, Kirsty Anne ^b   Solberg, Helene ^b   Lund, Leif Roge ^b   Romer, John ^b  

^a NOVO NORDISK A S   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900236135     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69057-5_11     Document Type: Chapter

References (91)

1. Abrahamsohn P. A., and Zorn T. M. T. 1993. Implantation and decidualization in rodents. J. Exp. Zool. 266:603-628.
2. Alexander C. M., Hansell E. J., Behrendtsen O., Flannery M. L., Kishnani N. S., Hawkes S. P., and Werb Z. 1996a. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary duringmouse embryo implantation.Development 122:1723-1736.
3. Alexander C. M., Howard E. W., Bissell M. J., and Werb Z. 1996b. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J. Cell Biol. 135:1669-1677.
4. Alexander C. M., Selvarajan S., Mudgett J., and Werb Z. 2001. Stromelysin-1 regulates adipogenesis during mammary gland involution. J. Cell Biol. 152:693-703.
5. Almholt K., Nielsen B. S., Frandsen T. L., Bruner N., Dano K., and Johnsen M. 2003. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 22:4389-4397.
6. Almholt K., Lund L. R., Rygaard J., Nielsen B. S., Dano K., Romer J., and Johnsen M. 2005. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int. J. Cancer 113:525-532.
7. Almholt K., Green K. A., Juncker-Jensen A., Nielsen B. S., Lund L. R., and Romer J. 2007. Extracellular proteolysis in transgenic mouse models of breast cancer. J. Mammary Gland Biol. Neoplasia 12:83-97.
8. Andreasen P. A., Kjoler L., Christensen L., and Duffy M. J. 1997. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer 72:1-22.
9. Andreasen P. A., Egelund R., and Petersen H. H. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57:25-40.
10. Bajou K., Noe A., Gerard R. D., Masson V., Bruner N., Holst-Hansen C., Skobe M., Fusenig N. E., Carmeliet P., Collen D., and Foidart J. M. 1998. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4:923-928.
11. Bajou K., Masson V., Gerard R. D., Schmitt P. M., Albert V., Praus M., Lund L. R., Frandsen T. L., Bruner N., Dano K., Fusenig N. E., Weidle U., Carmeliet G., Loskutoff D., Collen D., Carmeliet P., Foidart J. M., and Noel A. 2001. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: Implications for antiangiogenic strategies. J. Cell Biol. 152:777-784.
12. Balb? M., Fueyo A., Knaper V., Loez J. M.,A ?lvarez J., Sachez L. M., Quesada V., Bordallo J., Murphy G., and Loez-Ot? C. 2001. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J. Biol. Chem. 276:10253-10262.
13. Beare A. H., OKane S., Krane S. M., and Ferguson M. W. 2003. Severely impaired wound healing in the collagenase-resistant mouse. J. Invest. Dermatol. 120:153-163.
14. Blasi F., and Carmeliet P. 2002. uPAR: A versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3:932-943.
15. Bugge T. H., Flick M. J., Daugherty C. C., and Degen J. L. 1995a. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9:794-807.
16. Bugge T. H., Suh T. T., Flick M. J., Daugherty C. C., Romer J., Solberg H., Ellis V., Dano K., and Degen J. L. 1995b. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 270:16886-16894.
17. Bugge T. H., Flick M. J., Danton M. J., Daugherty C. C., Romer J., Dano K., Carmeliet P., Collen D., and Degen J. L. 1996a. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA 93:5899-5904.
18. Bugge T. H., Kombrinck K. W., Flick M. J., Daugherty C. C., Danton M. J., and Degen J. L. 1996b. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87:709-719.
19. Bugge T. H., Lund L. R., Kombrinck K. K., Nielsen B. S., Holmba k K., Drew A. F., Flick M. J., Witte D. P., Dano K., and Degen J. L. 1998. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16:3097-3104.
20. Bullard K. M., Lund L., Mudgett J. S., Mellin T. N., Hunt T. K., Murphy B., Ronan J., Werb Z., and Banda M. J. 1999. Impaired wound contraction in stromelysin-1-deficient mice. Ann. Surg. 230:260-265.
21. Carmeliet P., Kieckens L., Schoonjans L., Ream B., van Nuffelen A., Prendergast G., Cole M., Bronson R., Collen D., and Mulligan R. C. 1993. Plasminogen activator inhibitor-1 genedeficient mice. I Generation by homologous recombination and characterization. J. Clin. Invest. 92:2746-2755.
22. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J. J., Collen D., and Mulligan R. C. 1994. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419-424.
23. Clark R. A. F. (ed) 1996. The Molecular and Cellular Biology of Wound Repair. 2nd edn. New York: NY Plenum Press.
24. Collen D., and Lijnen H. R. 2005. Thrombolytic agents. Thromb. Haemost. 93:627-630.
25. Cross J. C., Werb Z., and Fisher S. J. 1994. Implantation and the placenta: Key pieces of the development puzzle. Science 266:1508-1518.
26. Czekay R. P., Aertgeerts K., Curriden S. A., and Loskutoff D. J. 2003. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 160:781-791.
27. Dano K., Behrendt N., Hoer-Hansen G., Johnsen M., Lund L. R., Ploug M., and Romer J. 2005. Plasminogen activation and cancer. Thromb. Haemost. 93:676-681.
28. Das S. K., Yano S., Wang J., Edwards D. R., Nagase H., and Dey S. K. 1997. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. Dev. Genet. 21:44-54.
29. Dellas C., and Loskutoff D. J. 2005. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb. Haemost. 93:631-640.
30. Dewerchin M., Nuffelen A. V., Wallays G., Bouche A., Moons L., Carmeliet P., Mulligan R. C., and Collen D. 1996. Generation and characterization of urokinase receptor-deficient mice. J. Clin. Invest. 97:870-878.
31. Dickson S. R., and Warburton M. J. 1992. Enhanced synthesis of gelatinase and stromelysin by myoepithelial cells during involution of the rat mammary gland. J. Histochem. Cytochem. 40:697-703.
32. Dougherty K. M., Pearson J. M., Yang A. Y., Westrick R. J., Baker M. S., and Ginsburg D. 1999. The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc. Natl. Acad. Sci. USA 96:686-691.
33. Dvorak H. F. 1986. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315:1650-1659.
34. Dvorak H. F., Brown L. F., Detmar M., and Dvorak A. M. 1995. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029-1039.
35. Fata J. E., Leco K. J., Voura E. B., Yu H. Y., Waterhouse P., Murphy G., Moorehead R. A., and Khokha R. 2001. Accelerated apoptosis in the Timp-3-deficient mammary gland. J. Clin. Invest. 108:831-841.
36. Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E., and Blasi F. 1997. A urokinasesensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16:7279-7286.
37. Folgueras A. R., Penda A. M., Sachez L. M., and Loez-Ot? C. 2004. Matrix metalloproteinases in cancer: From new functions to improved inhibition strategies. Int. J. Dev. Biol. 48:411-424.
38. Green K. A., and Lund L. R. 2005. ECM degrading proteases and tissue remodelling in the mammary gland. BioEssays 27:894-903.
39. Green K. A., Nielsen B. S., Castellino F. J., Romer J., and Lund L. R. 2006. Lack of plasminogen leads to milk stasis and premature mammary gland involution during lactation. Dev. Biol. 299:164-175.
40. Gutierrez L. S., Schulman A., Brito-Robinson T., Noria F., Ploplis V. A., and Castellino F. J. 2000. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 60:5839-5847.
41. Gutierez-Fernadez A., Inada M., Balb? M., Fueyo A., Pitiot A. S., Astudillo A., Hirose K., Hirata M., Shapiro S. D., Noe A., Werb Z., Krane S. M., Loez-Ot? C., and Puente X. S. 2007. Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8). FASEB J. 21:2580-2591.
42. Guy C. T., Cardiff R. D., and Muller W. J. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954-961.
43. Hartenstein B., Dittrich B. T., Stickens D., Heyer B., Vu T. H., Teurich S., Schorpp-Kistner M., Werb Z., and Angel P. 2006. Epidermal development and wound healing in matrix metalloproteinase 13-deficient mice. J. Invest. Dermatol. 126:486-496.
44. Hoyer-Hansen G., Behrendt N., Ploug M., Dano K., and Preissner K. T. 1997. The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction. FEBS Lett. 420:79-85.
45. Jodele S., Blavier L., Yoon J. M., and DeClerck Y. A. 2006. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 25:35-43.
46. Johnsen M., Lund L. R., Romer J., Almholt K., and Dano K. 1998. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol. 10:667-671.
47. Kawata Y., Mimuro J., Kaneko M., Shimada K., and Sakata Y. 1996. Expression of plasminogen activator inhibitor 2 in the adult and embryonic mouse tissues. Thromb. Haemost. 76:569-576.
48. Kirby D. R. S. 1965. The invasiveness of the trophoblast. In The Early Conceptus, Normal and Abnormal, ed. W. W. Park, pp. 68-74. Edinburgh: University of St. Andrews Press.
49. Lapiere C. M. 2003. Collagenase and impaired wound healing. J. Invest. Dermatol. 120:12-13.
50. Lefebvre O., Wolf C., Limacher J. M., Hutin P., Wendling C., LeMeur M., Basset P., and Rio M.-C. 1992. The breast cancer-Associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis. J. Cell Biol. 119:997-1002.
51. Li F., Strange R., Friis R. R., Djonov V., Altermatt H. J., SauRomer S., Niemann H., and Andres A. C. 1994. Expression of stromelysin-1 and TIMP-1 in the involuting mammary gland and in early invasive tumors of the mouse. Int. J. Cancer 59:560-568.
52. Liu X., Wu H., Byrne M., Jeffrey J., Krane S., and Jaenisch R. 1995. A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling. J. Cell Biol. 130:227-237.
53. Loez-Ot? C., and Overall C. M. 2002. Protease degradomics: A new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 3:509-519.
54. Loskutoff D. J., Curriden S. A., Hu G., and Deng G. 1999. Regulation of cell adhesion by PAI-1. APMIS 107:54-61.
55. Lund L. R., Romer J., Thomasset N., Solberg H., Pyke C., Bissell M. J., Dano K., and Werb Z. 1996. Two distinct phases of apoptosis in mammary gland involution: Proteinase-independent and -dependent pathways. Development 122:181-193.
56. Lund L. R., Romer J., Bugge T. H., Nielsen B. S., Frandsen T. L., Degen J. L., Stephens R. W., and Dano K. 1999. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 18:4645-4656.
57. Lund L. R., Bjon S. F., Sternlicht M. D., Nielsen B. S., Solberg H., Usher P. A., oterby R., Christensen I J., Stephens R. W., Bugge T. H., Dano K., and Werb Z. 2000. Lactational competence and involution of the mouse mammary gland require plasminogen. Development 127:4481-4492.
58. Lund L. R., Green K. A., Stoop A. A., Ploug M., Almholt K., Lilla J., Nielsen B. S., Christensen I J., Craik C. S., Werb Z., Dano K., and Romer J. 2006. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J. 25:2686-2697.
59. Madlener M., Parks W. C., and Werner S. 1998. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp. Cell Res. 242:201-210.
60. Martin P. 1997. Wound healing-Aiming for perfect skin regeneration. Science 276:75-81.
61. Mirastschijski U., Zhou Z., Rollman O., Tryggvason K., and \gren M. S. 2004. Wound healing in membrane-type-1 matrix metalloproteinase-deficient mice. J. Invest. Dermatol. 123:600-602.
62. Mohan R., Chintala S. K., Jung J. C., Villar W. V., McCabe F., Russo L. A., Lee Y., McCarthy B. E., Wollenberg K. R., Jester J. V., Wang M., Welgus H. G., Shipley J. M., Senior R. M., and Fini M. E. 2002. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. J. Biol. Chem. 277:2065-2072.
63. Nagase H., Visse R., and Murphy G. 2006. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69:562-573.
64. Page-McCaw A., Ewald A. J., and Werb Z. 2007. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8:221-233.
65. Pass J., Jogi A., Lund I K., Rono B., Rasch M. G., Ga?rdsvoll H., Lund L. R., Ploug M., Romer J., Dano K., and Hoyer-Hansen G. 2007. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Thromb. Haemost. 97:1013-1022.
66. Pedersen T. X., Pennington C. J., Almholt K., Christensen I J., Nielsen B. S., Edwards D. R., Romer J., Dano K., and Johnsen M. 2005. Protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis 26:1233-1240.
67. Ploplis V. A., Carmeliet P., Vazirzadeh S., Van Vlaenderen I., Moons L., Plow E. F., and Collen D. 1995. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 92:2585-2593.
68. Ploug M. 2003. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr. Pharm. Des. 9:1499-1528.
69. Reponen P., Leivo I., Sahlberg C., Apte S. S., Olsen B. R., Thesleff I., and Tryggvason K. 1995. 92-kDa type IV collagenase and TIMP-3, but not 72-kDa type IV collagenase or TIMP-1 or TIMP-2, are highly expressed during mouse embryo implantation. Dev. Dyn. 202:388-396.
70. Rinkenberger J., and Werb Z. 2000. The labyrinthine placenta. Nat. Genet. 25:248-250.
71. Rinkenberger J. L., Cross J. C., and Werb Z. 1997. Molecular genetics of implantation in the mouse. Dev. Genet. 21:6-20.
72. Rossant J., and Cross J. C. 2001. Placental development: Lessons from mouse mutants. Nat. Rev. Genet. 2:538-548.
73. Romer J. 2003. Skin cancer and wound healing. Tissue-specific similarities in extracellular proteolysis. APMIS Suppl. 107:5-36.
74. Romer J., Lund L. R., Eriksen J., Ralfki? E., Zeheb R., Gelehrter T. D., Dano K., and Kristensen P. 1991. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J. Invest. Dermatol. 97:803-811.
75. Romer J., Lund L. R., Eriksen J., Pyke C., Kristensen P., and Dano K. 1994. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J. Invest. Dermatol. 102:519-522.
76. Romer J., Bugge T. H., Pyke C., Lund L. R., Flick M. J., Degen J. L., and Dano K. 1996. Impaired wound healing in mice with a disrupted plasminogen gene. Nat. Med. 2:287-292.
77. Sappino A. P., Huarte J., Belin D., and Vassalli J. D. 1989. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J. Cell Biol. 109:2471-2479.
78. Selvarajan S., Lund L. R., Takeuchi T., Craik C. S., and Werb Z. 2001. A plasma kallikreindependent plasminogen cascade required for adipocyte differentiation.Nat. Cell Biol. 3:267-275.
79. Singer A. J., and Clark R. A. 1999. Cutaneous wound healing. N. Engl. J. Med. 341:738-746.
80. Solberg H., Rinkenberger J., Dano K., Werb Z., and Lund L. R. 2003. A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development 130:4439-4450.
81. Stefansson S., and Lawrence D. A. 1996. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 383:441-443.
82. Strickland S., and Richards W. G. 1992. Invasion of the trophoblasts. Cell 71:355-357.
83. Suh T. T., Holmba k K., Jensen N. J., Daugherty C. C., Small K., Simon D. I., Potter S. S., and Degen J. L. 1995. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 9:2020-2033.
84. Sympson C. J., Talhouk R. S., Alexander C. M., Chin J. R., Clift S. M., Bissell M. J., and Werb Z. 1994. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J. Cell Biol. 125:681-693.
85. Szabova L., Yamada S. S., Birkedal-Hansen H., and Holmbeck K. 2005. Expression pattern of four membrane-type matrix metalloproteinases in the normal and diseased mouse mammary gland. J. Cell. Physiol. 205:123-132.
86. Talhouk R. S., Bissell M. J., and Werb Z. 1992. Coordinated expression of extracellular matrixdegrading proteinases and their inhibitors regulates mammary epithelial function during involution. J. Cell Biol. 118:1271-1282.
87. Teesalu T., Blasi F., and Talarico D. 1996. Embryo implantation in mouse: Fetomaternal coordination in the pattern of expression of uPA, uPAR, PAI-1 and alpha 2MR/LRP genes. Mech. Dev. 56:103-116.
88. Wei Y., Waltz D. A., Rao N., Drummond R. J., Rosenberg S., and Chapman H. A. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:32380-32388.
89. Werner S., and Grose R. 2003. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 83:835-870.
90. Wu H., Liu X., and Jaenisch R. 1994. Double replacement: Strategy for efficient introduction of subtle mutations into the murine Col1a-1 gene by homologous recombination in embryonic stem cells. Proc. Natl. Acad. Sci. USA 91:2819-2823.
91. Yamazaki M., Akahane T., Buck T., Yoshiji H., Gomez D. E., Schoeffner D. J., Okajima E., Harris S. R., Bunce O. R., Thorgeirsson S. S., and Thorgeirsson U. P. 2004. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Carcinogenesis 25:1735-1746